SMA Europe responds to European neuromuscular experts’ consensus statements on gene replacement therapy for SMA
A group of European neuromuscular experts presented eleven consensus statements covering qualification, patient selection, safety considerations and long-term monitoring, in order to aid the rational use of Zolgensma™ for the treatment of SMA (1). In a letter published in the European Journal of Paediatric Neurology (2), SMA Europe addresses these consensus statements by highlights: The […]